Lv1
28 积分 2024-12-30 加入
Stapokibart: First Approval
3天前
已完结
Effects of a Novel Dual Phosphodiesterase 3 and 4 Inhibitor TQC3721 in Patients with COPD in China (PACER-II): a phase 2, multicentre, randomised, double-blind, placebo-controlled trial
10天前
已完结
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
14天前
已完结
T follicular helper cells in IgE-mediated pathologies
15天前
已完结
Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trial
15天前
已完结
The role of IL-2 cytokine family in asthma
23天前
已完结
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
23天前
已完结
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
23天前
已完结
B7-H3-mediated cis-inhibition of EGFR by a tumor-selective bispecific antibody enhances anti-tumor efficacy and minimizes toxicities
30天前
已关闭
JAK inhibitor selectivity: new opportunities, better drugs?
1个月前
已完结
皖公网安备34019202002308
